JP2020189845A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020189845A5 JP2020189845A5 JP2020127888A JP2020127888A JP2020189845A5 JP 2020189845 A5 JP2020189845 A5 JP 2020189845A5 JP 2020127888 A JP2020127888 A JP 2020127888A JP 2020127888 A JP2020127888 A JP 2020127888A JP 2020189845 A5 JP2020189845 A5 JP 2020189845A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- fibrosis
- inhibitor
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 239000003112 inhibitor Substances 0.000 claims 14
- 206010016654 Fibrosis Diseases 0.000 claims 12
- 230000004761 fibrosis Effects 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000004452 carbocyclyl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 5
- 239000000758 substrate Substances 0.000 claims 5
- 125000002252 acyl group Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 102000004400 Aminopeptidases Human genes 0.000 claims 3
- 108090000915 Aminopeptidases Proteins 0.000 claims 3
- 108010035532 Collagen Proteins 0.000 claims 3
- 102000008186 Collagen Human genes 0.000 claims 3
- 102000012422 Collagen Type I Human genes 0.000 claims 3
- 108010022452 Collagen Type I Proteins 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 125000005884 carbocyclylalkyl group Chemical group 0.000 claims 3
- -1 carboxyester Chemical group 0.000 claims 3
- 230000015556 catabolic process Effects 0.000 claims 3
- 229920001436 collagen Polymers 0.000 claims 3
- 238000006731 degradation reaction Methods 0.000 claims 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 125000005133 alkynyloxy group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 230000008021 deposition Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 125000000686 lactone group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 206010001580 Albuminuria Diseases 0.000 claims 1
- QSBGWDDCOJYQGY-KOQODJNWSA-N Angiotensin IV Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)C(C)C)C1=CC=C(O)C=C1 QSBGWDDCOJYQGY-KOQODJNWSA-N 0.000 claims 1
- 108090000672 Annexin A5 Proteins 0.000 claims 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical group [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- JIZRUFJGHPIYPS-SRVKXCTJSA-N Cys-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CS)N)O JIZRUFJGHPIYPS-SRVKXCTJSA-N 0.000 claims 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010058222 Hypertensive cardiomyopathy Diseases 0.000 claims 1
- 239000004395 L-leucine Substances 0.000 claims 1
- 235000019454 L-leucine Nutrition 0.000 claims 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000005035 acylthio group Chemical group 0.000 claims 1
- 125000003302 alkenyloxy group Chemical group 0.000 claims 1
- 125000005108 alkenylthio group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000005109 alkynylthio group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000005110 aryl thio group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 150000001540 azides Chemical class 0.000 claims 1
- 238000001649 capillary isotachophoresis Methods 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 229940109239 creatinine Drugs 0.000 claims 1
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 210000002744 extracellular matrix Anatomy 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 230000009791 fibrotic reaction Effects 0.000 claims 1
- 230000024924 glomerular filtration Effects 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000005368 heteroarylthio group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims 1
- 125000004468 heterocyclylthio group Chemical group 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 208000015210 hypertensive heart disease Diseases 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 230000002452 interceptive effect Effects 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 229960003136 leucine Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000000651 myofibroblast Anatomy 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 230000004768 organ dysfunction Effects 0.000 claims 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 201000001474 proteinuria Diseases 0.000 claims 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 230000008085 renal dysfunction Effects 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 150000003384 small molecules Chemical group 0.000 claims 1
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 1
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022199857A JP2023030022A (ja) | 2015-07-30 | 2022-12-15 | 線維症の処置 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015903035 | 2015-07-30 | ||
| AU2015903035A AU2015903035A0 (en) | 2015-07-30 | Fibrotic treatment | |
| JP2018504650A JP2018527330A (ja) | 2015-07-30 | 2016-07-29 | 線維症の処置 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018504650A Division JP2018527330A (ja) | 2015-07-30 | 2016-07-29 | 線維症の処置 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022199857A Division JP2023030022A (ja) | 2015-07-30 | 2022-12-15 | 線維症の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020189845A JP2020189845A (ja) | 2020-11-26 |
| JP2020189845A5 true JP2020189845A5 (cg-RX-API-DMAC7.html) | 2021-04-01 |
| JP7457360B2 JP7457360B2 (ja) | 2024-03-28 |
Family
ID=57883919
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018504650A Withdrawn JP2018527330A (ja) | 2015-07-30 | 2016-07-29 | 線維症の処置 |
| JP2020127888A Active JP7457360B2 (ja) | 2015-07-30 | 2020-07-29 | 線維症の処置 |
| JP2022199857A Pending JP2023030022A (ja) | 2015-07-30 | 2022-12-15 | 線維症の処置 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018504650A Withdrawn JP2018527330A (ja) | 2015-07-30 | 2016-07-29 | 線維症の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022199857A Pending JP2023030022A (ja) | 2015-07-30 | 2022-12-15 | 線維症の処置 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US10100311B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3328384B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2018527330A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016301113B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3017028C (cg-RX-API-DMAC7.html) |
| HK (1) | HK1256423A1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201808478RA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017015720A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3294721A4 (en) * | 2015-05-08 | 2018-11-07 | Monash University | 4h-pyran compounds as insulin-regulated aminopeptidase (irap) inhibitors |
| EP3328384B1 (en) | 2015-07-30 | 2020-07-29 | Monash University | Fibrotic treatment |
| US11331368B2 (en) * | 2017-07-17 | 2022-05-17 | Monash University | Angiotensin receptor agonists and uses thereof |
| EP3902460A4 (en) * | 2018-12-28 | 2023-01-11 | The General Hospital Corporation | ANTI-EPHRIN B2 BLOCKER ANTIBODIES FOR THE TREATMENT OF FIBROTIC DISEASES |
| WO2021050089A1 (en) * | 2019-09-09 | 2021-03-18 | Washington State University | Genetic test for identifying cats at a high risk for developing tubulointerstitial fibrosis |
| CN115427060A (zh) | 2020-02-19 | 2022-12-02 | 海必恩制药公司 | 环孢菌素类似物用于治疗纤维化的用途 |
| JP2024543981A (ja) * | 2021-12-01 | 2024-11-26 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 炎症性疾患の処置に使用するためのｉｒａｐアミノペプチダーゼ阻害剤の使用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1789079T3 (da) * | 2004-09-09 | 2013-03-11 | Florey Howard Inst | Insulinregulrede aminopeptidase (IRAP)-inhibitorer og anvendelser deraf |
| MX2008002431A (es) * | 2005-08-23 | 2008-04-03 | Wyeth Corp | Metodos para el tratamiento contra ansiedad y para identificacion de agentes ansioliticos. |
| NZ585338A (en) * | 2007-11-19 | 2012-08-31 | Howard Florey Inst | Insulin-regulated aminopeptidase (irap) inhibitors and uses thereof |
| US20150057216A1 (en) * | 2011-12-16 | 2015-02-26 | Tarix Pharmaceuticals Ltd. | Angiotensins for treatment of fibrosis |
| AU2013218148A1 (en) * | 2012-02-06 | 2014-07-24 | Glaxosmithkline Intellectual Property (No. 2) Limited | PI3K inhibitors for treating fibrotic diseases |
| JP6327923B2 (ja) | 2014-04-25 | 2018-05-23 | 旭化成株式会社 | ポリアセタール樹脂組成物、及びそれからなる成形体 |
| DE102014114090A1 (de) | 2014-09-29 | 2016-03-31 | Karlsruher Institut für Technologie | Verfahren zur Abtrennung von Aluminium bei der Calciumsilikatproduktion |
| US9519061B2 (en) * | 2014-12-26 | 2016-12-13 | Here Global B.V. | Geometric fingerprinting for localization of a device |
| EP3294721A4 (en) * | 2015-05-08 | 2018-11-07 | Monash University | 4h-pyran compounds as insulin-regulated aminopeptidase (irap) inhibitors |
| EP3328384B1 (en) * | 2015-07-30 | 2020-07-29 | Monash University | Fibrotic treatment |
-
2016
- 2016-07-29 EP EP16829507.9A patent/EP3328384B1/en active Active
- 2016-07-29 AU AU2016301113A patent/AU2016301113B2/en active Active
- 2016-07-29 WO PCT/AU2016/050681 patent/WO2017015720A1/en not_active Ceased
- 2016-07-29 JP JP2018504650A patent/JP2018527330A/ja not_active Withdrawn
- 2016-07-29 HK HK18115556.4A patent/HK1256423A1/zh unknown
- 2016-07-29 CA CA3017028A patent/CA3017028C/en active Active
- 2016-07-29 SG SG11201808478RA patent/SG11201808478RA/en unknown
- 2016-07-29 US US15/747,697 patent/US10100311B2/en active Active
-
2018
- 2018-09-06 US US16/123,898 patent/US10787668B2/en active Active
-
2020
- 2020-07-29 JP JP2020127888A patent/JP7457360B2/ja active Active
- 2020-08-04 US US16/984,996 patent/US11078488B2/en active Active
-
2021
- 2021-07-01 US US17/365,260 patent/US11834663B2/en active Active
-
2022
- 2022-12-15 JP JP2022199857A patent/JP2023030022A/ja active Pending
-
2023
- 2023-10-26 US US18/495,512 patent/US20240084308A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020189845A5 (cg-RX-API-DMAC7.html) | ||
| JP2018527330A5 (cg-RX-API-DMAC7.html) | ||
| JP6526306B2 (ja) | バルドキソロンメチルまたはその類似体を使用して内皮機能障害を処置および予防する方法 | |
| ES2892954T3 (es) | Derivados fluorados del ácido 3-(2-oxo-3-(3-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)propil)imidazolidin-1-il)propanoico y usos de los mismos | |
| JP4692281B2 (ja) | 新規アゾール化合物 | |
| JP3187535B2 (ja) | 医薬的に活性なヒドラジン誘導体およびその製造方法 | |
| BR122018015003B1 (pt) | kit compreendendo composições farmacêuticas de inibidor da nep e de valsartan ou seus sais | |
| JP2023030022A5 (cg-RX-API-DMAC7.html) | ||
| JP7457360B2 (ja) | 線維症の処置 | |
| JPWO2002092068A1 (ja) | カルボン酸誘導体化合物およびそれらを有効成分とする薬剤 | |
| JPH09506368A (ja) | 複素環式脱離基を含むシステインプロテアーゼインヒビター | |
| JPWO2007083689A1 (ja) | プラスミノーゲンアクチベーターインヒビター−１阻害剤 | |
| JPH08508720A (ja) | ピロールーアミジン化合物およびその薬剤的に受容できる塩、その製造法ならびにこれを含む医薬組成物 | |
| JP2021519312A (ja) | カルパインモジュレーター及びその治療的使用 | |
| JP5410278B2 (ja) | βセクレターゼ阻害活性を有する新規化合物 | |
| JP2003183254A (ja) | ２−アシルアミノ−３，５−ジシアノピリジン誘導体又はその塩 | |
| US12011427B2 (en) | Methods of treating cancer | |
| Lu et al. | Design, synthesis, and evaluation of pirfenidone-NSAIDs conjugates for the treatment of idiopathic pulmonary fibrosis | |
| US20190169185A1 (en) | Substituted 2-n-hydroxy-1,3-dioxo-1,2,3,4-tetrahydronaphthyridines, and methods of making and using same | |
| US20050130941A1 (en) | Methods of treating alzheimer's disease | |
| JP2023505598A (ja) | 化合物及びα１－アンチトリプシン欠損症の治療のためのそれらの使用 | |
| JP2002544119A (ja) | フェニルアラニン誘導体 | |
| TW201215389A (en) | Sustained-release therapeutic agent for hypertension and renal dysfunction | |
| JPH0529209B2 (cg-RX-API-DMAC7.html) | ||
| JP2003528850A (ja) | 血管形成および腫瘍成長の阻害 |